晶品特裝(688084.SH):在機器人領域,公司目前專注於研發生產特種機器人及核心部件
格隆匯10月27日丨有投資者在投資者互動平台向晶品特裝(688084.SH)提問,“請問貴公司是否生產人形機器人? 恰逢一帶一路論壇盛會,貴公司是否有產品參與到一帶一路?”
公司表示,在機器人領域,公司目前專注於研發生產特種機器人及核心部件。機器人形態包括輪式、履帶式、足式、複合式等,其中足式包括四足仿生和雙足仿人等,複合式包括輪足式、輪履式、足履式等。具體形態根據客户具體要求確定。一帶一路是國家發展戰略,公司將遵循國家法律法規積極參與國家戰略實施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.